about
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alphaCyclin-dependent kinase 4Fat mass and obesity associatedAcetyl-Coenzyme A acetyltransferase 1AT-rich interaction domain 5BTBL1X receptor 1Dual specificity tyrosine phosphorylation regulated kinase 1BRAR related orphan receptor CLDL receptor related protein 5Ubiquitin BInhibitor of DNA binding 2LDL receptor related protein 5 likeEBF transcription factor 2Activating transcription factor 2X-box binding protein 1PPARG coactivator 1 alphaPAX interacting protein 1Serine palmitoyltransferase long chain base subunit 2SRY-box transcription factor 8Selenoprotein MAcetoacetyl-CoA synthetaseUromodulin like 13-oxoacid CoA-transferase 1Solute carrier family 25 member 25SH3 and PX domains 2BZinc finger protein 516Serine palmitoyltransferase, long chain base subunit 2, isoform CRA_aSpastic paraplegia 20 isoform 1SpartinAPC membrane recruitment protein 1Low density lipoprotein receptor-related protein 5AT rich interactive domain 5B (MRF1-like)Adhesion regulating molecule 1CAMP responsive element binding protein 5APC membrane recruitment 1Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1bActivating transcription factor 2Berardinelli-Seip congenital lipodystrophy 2 (seipin)High mobility group AT-hook 2Acetoacetyl-CoA synthetase
P682
A form of the metabolic syndrome associated with mutations in DYRK1BNampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzymePatients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cellsLigand and Target Discovery by Fragment-Based Screening in Human Cells.
P921
Q14887711-EAA5F233-9C87-47F0-B9C8-132E251624B6Q14911756-8E3D4FAC-B105-4C23-BA45-4E8A0EAC9DE5Q14912507-9FF5B417-B407-4DE7-939F-E593486E97ACQ14913203-50E960F9-4858-4BE2-89E9-90F7CB0A9472Q21097438-CB228EA7-DE6D-4EA0-9520-F54FBD86AA71Q21097455-B5F90E43-DF5A-4AF4-BD17-86A7D662EED8Q21101045-5D959BA7-DEF5-4FED-A730-B3B8D66CDFD7Q21109596-57A5F60E-10DF-4BA9-B159-A2B40662E653Q21111886-07C06D49-2534-4E56-8B13-8C693E51E54DQ21111886-26B7B680-82AA-4458-B4BF-6D6627E7E497Q21112968-AB1F5760-83E3-4391-94F1-93753D72EC3BQ21113941-E88627AE-C011-49D3-B09F-2327D5C7718AQ21114905-CABAE2D3-858C-4B59-AE9A-798462632ADCQ21115681-3384082A-BA96-4C7B-9175-376461F49BA8Q21116768-28FA33D9-016D-4B4D-BF60-D83F93D3574BQ21116794-82B5D0B5-46FE-481A-972C-3A7BB76D1A66Q21118081-39BCCA34-606C-4C7E-9D41-C04E6FA60A70Q21121828-C22FE6AB-6B7F-4A01-9991-728434758A21Q21122109-EDAE75FB-B45C-4787-B0AA-4CDA8954CE69Q21127266-80B3F57C-53AE-4744-8A07-50A69E779CBAQ21130958-7D869B4E-BAA7-4B8C-B78E-DEE089573CF6Q21132857-54FA75EB-3EC4-40B9-9562-25F14F466258Q21135181-E8BFEAB6-5A26-4A17-9F27-38982987152DQ21135435-2C3B12D2-EA53-47DD-B684-1858BBA753B6Q21135443-23F38D29-DBE7-4CC4-BB18-70AD58F95C7FQ21135654-8B6729D4-8437-4748-BF19-5479B4FDACC3Q21136648-9ADD042C-C68F-4D7A-8007-EA9802B0ABBBQ21137102-49E73A7F-0DC7-4626-843A-B612517296E8Q21149301-8B88DB73-110B-4E79-990B-12233873EBACQ21173833-0995100A-25AA-4BC8-9FE4-7F3FBE3A0C70Q21245850-BAC055B2-598B-46ED-9FD7-0AE7AE5B9A78Q21495924-6B0C2B2A-1BD1-4F0F-B42A-247E8B42AFEEQ21495924-9087E4AE-8B3A-4DB0-A1F5-CC6626BE275DQ21496931-026EC103-F820-415A-A284-CBF0176012BEQ21496931-DE1FF01D-15C9-463F-9F38-6E0EE5F0E7A0Q21498873-ABF53FF3-DB5C-41FB-97D7-6D3CCCBC1ABDQ21499364-F14FE7ED-8275-49D2-A096-0CD94A4A595FQ21499481-773ABF45-8810-4ECB-8342-E5B1862823F1Q21981057-51936013-849D-48A5-8019-0ABAE24B4A82Q21981489-61CD6918-C1E3-4785-A52E-A489AD8F2099
P682
description
The process whose specific out ...... sue that is used to store fat.
@en
biologisch proces
@nl
name
adipose tissue development
@en
utvikling av feittvev
@nn
type
label
adipose tissue development
@en
utvikling av feittvev
@nn
altLabel
GO:0060612
@en
GO:0060612
@nn
prefLabel
adipose tissue development
@en
utvikling av feittvev
@nn
P2888
P686
GO:0060612